Celcuity Inc. (NAS: CELC) Stock Analysis & Fundamentals

CELCCelcuity Inc.

NAS · US · Healthcare · Biotechnology · celcuity.com

88.29USD-3.52%Mkt Cap: 4.31B $P/E: —1d ago

Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolis…

Headline	Source	Time
This week
Why This Biotech Stock, With Its First FDA Approval, Just Crashed By Double Digits Celcuity stock crashed Wednesday after the biotech delayed the launch of its just-approved breast cancer treatment until the third quarter.	Investor's Business Daily	1d
Celcuity shares fall as delayed breast cancer drug launch eclipses first US FDA approval July 15 () - Shares of Celcuity fell about 8% in premarket trading on Wednesday, as the delayed commercial launch ‌of its newly approved breast cancer drug and treatment-tolerability ‌concerns overshadowed the company's first U. Food and Drug Administration on Tuesday approved gedatolisib, branded as Revtorpyk, for certain patients with advanced breast cancer whose tumors do not carry a PIK3CA mutation.	Reuters	1d
Celcuity gains FDA approval for closely watched breast cancer drug Still, shares fell by nearly 20% after the company revealed a delay in the coming launch of Revtorpyk. Details in the drug’s prescribing information surprised some analysts, too.	BioPharma Dive	1d
Celcuity Enters Commercial Stage as FDA Approves REVTORPYK for Advanced Breast Cancer Celcuity (NASDAQ:CELC) said the U.S. Food and Drug Administration has granted full approval to gedatolisib, now branded as REVTORPYK, for certain patients with advanced breast cancer, marking the company’s transition to a commercial-stage business. Brian Sullivan, Celcuity’s co-founder and chief ex	MarketBeat	2d
CELC Stock Clocks Best Day In About 2 Months On First FDA Approval For Cancer Drug Gedatolisib, in-licensed from Pfizer in 2021, is Celcuity’s sole late-stage asset.	Stocktwits	Jul 14
Older
QURE Was Just the Beginning: 5 Biotech Catalysts I’m Watching Now	InvestorPlace	Jun 19
Celcuity (CELC) Weighs Dilution Against Drug Development After $500 Million Convertible Note Offering	Simply Wall St.	Jun 4
Celcuity (CELC) Expands Phase 3 VIKTORIA-2 Trial to Include Endocrine-Sensitive Breast Cancer Patients	Insider Monkey	Jun 4
US Equity Futures Mixed Pre-Bell as US, Iran Continue Military Strikes in Middle East	MT Newswires	Jun 3
CELC Stock Records Worst Day Ever After Late-Stage Breast Cancer Trial Results — What’s Driving The Selloff?	Stocktwits	Jun 2
Celcuity Crashes On Breast Cancer Disappointment. What Happened?	Investor's Business Daily	Jun 2
Celcuity Says Gedatolisib Outperforms Novartis' Alpelisib Plus Fulvestrant in Phase 3 Trial	MT Newswires	Jun 2
Celcuity breast cancer drug misses ‘lofty’ expectations in ASCO-spotlighted trial	BioPharma Dive	Jun 2
Celcuity Shares Fall Despite Strong Phase 3 Breast Cancer Trial Data (CELC)	InvestorsHub	Jun 2
Vericel Revenue Jumped 20%. One Biotech Investor Just Reported Adding $63 Million More	Motley Fool	May 30
Boxer Capital’s $18 Million Corvus Pharma Bet Signals Confidence in This Biotech’s Next Phase	Motley Fool	May 17
Vir Biotechnology Stock Has Doubled This Past Year. One Fund Just Bought 1.2 Million Shares	Motley Fool	May 17
Assessing Celcuity (CELC) Valuation After Positive VIKTORIA 1 Data And Upcoming FDA Decision	Simply Wall St.	May 16
Celcuity Inc (CELC) Q1 2026 Earnings Call Highlights: Promising Clinical Trials and Strategic ...	GuruFocus.com	May 15
Celcuity Q1 Earnings Call Highlights	MarketBeat	May 14
Celcuity (CELC) Q1 2026 Earnings Transcript	Motley Fool	May 14
Structure Therapeutics Stock Is Up 47%, but One Fund Just Fully Exited a $2.6 Million Position	Motley Fool	May 10
Why One Fund’s $4 Million Alumis Buy Looks Like a Bet on a Breakthrough Autoimmune Drug	Motley Fool	May 10
Is It Too Late To Consider Celcuity (CELC) After A 13x One Year Surge?	Simply Wall St.	May 6
Top Midday Gainers	MT Newswires	May 4

Industry Peers